Yahoo
    SES - Delayed Quote SGD

    China Medical System Holdings Limited (8A8.SI)

    1.5900 0.0000 (0.00%)
    At close: November 2 at 11:51:26 AM GMT+8
    Loading Chart for 8A8.SI
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China

    CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China
    GlobeNewswire 1mo ago
    CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)

    CMS(867.HK/8A8.SG): Innovative Drug Lumirix® Approved in China for Additional Indication of Atopic Dermatitis (AD)
    GlobeNewswire 1mo ago
    CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies

    CMS: Class 1 Innovative Drug Silevimig Injection Approved in China, Becoming the World’s First Bispecific Antibody for Passive Immunization Against Rabies
    GlobeNewswire 4mo ago
    CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions

    CMS's (867.HK/8A8.SG) Self-developed Innovative INHBE-Targeting siRNA Drug CMS-D008 Presents Its Preclinical Results at the ADA Scientific Sessions
    GlobeNewswire 4mo ago
    CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

    CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®
    GlobeNewswire 6mo ago
    CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

    CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China
    GlobeNewswire 6mo ago
    Leios Therapeutics Announces Exclusive Licensing Agreement and Strategic Investment with Subsidiaries of China Medical System Holdings Ltd. for 10XB-101

    Leios Therapeutics Announces Exclusive Licensing Agreement and Strategic Investment with Subsidiaries of China Medical System Holdings Ltd. for 10XB-101
    GlobeNewswire 2mo ago
    Beyang Closes Oversubscribed $30 Million Series A Financing

    Beyang Closes Oversubscribed $30 Million Series A Financing
    PR Newswire 2mo ago
    Beyang Closes Oversubscribed $30 Million Series A Financing

    Beyang Closes Oversubscribed $30 Million Series A Financing
    PR Newswire 2mo ago
    CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

    CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
    GlobeNewswire 8mo ago
    CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China

    CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China
    GlobeNewswire 10mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: